There's No Pill for Meth. Here's What Actually Moves the Needle.

John Vance was sitting in his car at 3 a.m. with a meth pipe when he noticed something that should have been obvious years earlier and wasn’t: the hit wasn’t doing what it was supposed to do. He smoked, and instead of relief, his anxiety climbed. He’d been using since college — LSD first, then alcohol, then methamphetamine and heroin injected daily by the end of a PhD program that somehow still produced an English professor. He was homeless by then, his mother-in-law raising his son. “It took me personally, in a selfish way, to realize it wasn’t making me feel good anymore,” he later said. That gap — between what the drug promises and what it delivers once your brain has rewired itself around it — is the entire clinical problem methamphetamine treatment is trying to solve, and medicine still doesn’t have a reliable tool for closing it.

Methamphetamine use disorder has no FDA-approved medication. Zero. Not one. Opioid use disorder has three. Alcohol use disorder has three more. Stimulants — meth and cocaine together — were tied to close to 60% of U.S. overdose deaths between 2021 and mid-2024, nearly half of them alongside an opioid, and the treatment system built around them has nothing to prescribe. Dozens of compounds have been tried. None has cleared the bar. If you are the person craving methamphetamine at 3 a.m., the honest clinical answer, until very recently, has been: we don’t have a pill for you.

A cheap antidepressant is the first real crack in that wall

In April, JAMA Psychiatry published the results of a phase 3 trial led by researcher Rebecca McKetin that ran across six outpatient addiction clinics in Australia from late 2022 to mid-2025. The drug being tested wasn’t new or exotic — it was mirtazapine, a decades-old antidepressant sold generically for pennies a pill. At 30 milligrams a day, it produced about two fewer days of methamphetamine use per month compared to placebo. Two days. That is not a cure, and nobody running the trial called it one.

Here’s what makes it matter anyway. When researchers looked at why mirtazapine was working, they expected to find it was simply treating the depression and insomnia that so often ride alongside heavy meth use — fix the sleep, fix the mood, and the using follows. That’s not what they found. The reduction in methamphetamine use showed up independent of whether someone’s depression or sleep actually improved, which means mirtazapine appears to be doing something more direct: turning down the volume on the drug’s rewarding effect itself, not just treating its collateral damage. In plain terms — it may be dulling the craving mechanism, not just the symptoms craving produces. That distinction is why a $4-a-month generic that any primary care doctor can prescribe, no special licensing required, no induction protocol, is being talked about as a genuine advance rather than a footnote.

It joins one other option with real evidence behind it: the combination of extended-release injectable naltrexone and oral bupropion, first shown effective in the 2021 ADAPT-2 trial — 27% of participants on the combination had methamphetamine-negative urine tests over 12 weeks, compared to 11% on placebo. Neither mirtazapine nor naltrexone-bupropion is FDA-approved specifically for methamphetamine use disorder; both are prescribed off-label, which is part of why the FDA announced steps in August to make it easier for companies to run the trials that could change that. Layer them with contingency management — the behavioral approach that pays people small, real incentives for negative drug tests, still the best-evidenged intervention stimulant treatment has — and you get what researchers are now calling a layered model instead of a single silver bullet. Psychiatrist Mark Gold, who has spent four decades studying stimulant treatment, put it this way: modest, layered gains are what this field actually looks like right now, and pretending otherwise has cost people years.

The drug war tried to fix this from the supply side. It didn’t work, and you’re living with the result

We’ve watched a version of this before. In 2005, Congress passed the Combat Methamphetamine Epidemic Act, restricting retail pseudoephedrine — the cold-medicine precursor — specifically to shut down small domestic meth labs. It worked exactly as designed: home-cook “shake and bake” labs mostly disappeared from American kitchens within a few years. What replaced them was worse. Mexican trafficking organizations scaled up industrial production using unregulated precursor chemistry, and meth got purer, cheaper, and more available than the labs it replaced ever managed. Two decades later, treatment capacity looks almost exactly like it did before the 2005 law: still built around a pharmacological toolkit that doesn’t include the drug actually driving the crisis. Supply-side policy changed who profited. It never touched the gap John Vance sat inside at 3 a.m.

In 2005, Congress passed the Combat Methamphetamine Epidemic Act, restricting retail pseudoephedrine — the cold-medicine precursor — specifically to shut down small domestic meth labs.

If you’re in that gap right now — using more than you want to, feeling less from it every time, telling yourself the next hit will get back to how it used to feel — the craving you’re fighting isn’t a character problem. It’s neurobiology that has been reshaped by repeated exposure, and it responds, however imperfectly right now, to actual treatment: medication that blunts the reward, incentives that make not-using tangibly worth something today, and people around you who’ve been exactly where you are. Vance found his through a therapeutic community in Lexington, Kentucky, and a job at a restaurant that hires people in recovery; the breakthrough wasn’t the pipe he put down, it was realizing sober people could still be interesting to be around. “You gotta learn how to be anxious without getting high,” he says now, four years out, counseling incarcerated people through the same withdrawal he survived.

For case managers building a referral pathway today: ask whether your state Medicaid plan reimburses contingency management (a growing number now do, including Arizona’s AHCCCS under a 2023 pilot expansion) before assuming it’s unavailable to a client — it is frequently the single highest-yield stimulant intervention sitting unused for lack of a billing code someone bothered to look up.

Mirtazapine won’t end the stimulant crisis, and nobody serious is claiming it will. What it does is smaller and, for the person actually living with the craving, arguably more useful: it’s proof the reward circuit methamphetamine hijacks isn’t untouchable. Two fewer days a month isn’t victory. It’s evidence that the wall has a crack in it, and for the first time in a while, medicine is aiming at the right target.